Saltar al contenido
Merck

D4681

Sigma-Aldrich

L-threo-Dihydrosphingosine

≥95% (TLC)

Sinónimos:

Safingol

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización


About This Item

Fórmula empírica (notación de Hill):
C18H39NO2
Número de CAS:
Peso molecular:
301.51
Número MDL:
Código UNSPSC:
12352211
ID de la sustancia en PubChem:
NACRES:
NA.77

Nivel de calidad

Ensayo

≥95% (TLC)

Formulario

powder

temp. de almacenamiento

−20°C

cadena SMILES

CCCCCCCCCCCCCCC[C@H](O)[C@@H](N)CO

InChI

1S/C18H39NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-18(21)17(19)16-20/h17-18,20-21H,2-16,19H2,1H3/t17-,18-/m0/s1

Clave InChI

OTKJDMGTUTTYMP-ROUUACIJSA-N

Acciones bioquímicas o fisiológicas

Sphingosine kinase inhibitor; protein kinase C alpha (PKCα) -specific inhibitor; Sphingosine analog; potentiates the effect of doxorubicin (DOX) in tumor-bearing animals.

Código de clase de almacenamiento

11 - Combustible Solids

Clase de riesgo para el agua (WGK)

WGK 3

Punto de inflamabilidad (°F)

Not applicable

Punto de inflamabilidad (°C)

Not applicable

Equipo de protección personal

Eyeshields, Gloves, type N95 (US)


Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

¿No ve la versión correcta?

Si necesita una versión concreta, puede buscar un certificado específico por el número de lote.

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

G K Schwartz et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 3(4), 537-543 (1997-04-01)
We performed a pilot clinical trial with safingol (L-threo-dihydrosphingosine), a protein kinase C-specific inhibitor that potentiates the effect of doxorubicin (DOX) in tumor-bearing animals. Safingol was initially administered as a 1-h infusion at escalating doses. Fourteen days later, patients received
Yi-Hsin Hsu et al.
Cancer research, 74(17), 4822-4835 (2014-06-28)
Triple-negative breast cancer (TNBC) is a highly heterogeneous and recurrent subtype of breast cancer that lacks an effective targeted therapy. To identify candidate therapeutic targets, we profiled global gene expression in TNBC and breast tumor-initiating cells with a patient survival
J W Darges et al.
Advances in experimental medicine and biology, 400A, 387-392 (1997-01-01)
The sphingosine analog L-threo-dihydrosphingosine has been shown to inhibit protein kinase C (PKC) isoenzymes in mixed micelle and vesicle assays. This compound also inhibited the reactive oxygen intermediates (ROI) released from isolated neutrophils (IC50 approximately 2 microM) and phorbol ester-induced
Emma M Dangerfield et al.
Chembiochem : a European journal of chemical biology, 13(9), 1349-1356 (2012-05-29)
The immunomodulatory glycolipid α-galactosylceramide (α-GalCer) binds to CD1d and exhibits potent activity as a ligand for invariant CD1d-restricted natural killer-like T cells (iNKT cells). Structural analogues of α-GalCer have been synthesised to determine which components are required for CD1d presentation
Yidi Sun et al.
Molecular biology of the cell, 23(12), 2388-2398 (2012-04-27)
Sphingoid intermediates accumulate in response to a variety of stresses, including heat, and trigger cellular responses. However, the mechanism by which stress affects sphingolipid biosynthesis has yet to be identified. Recent studies in yeast suggest that sphingolipid biosynthesis is regulated

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico